There are a couple of things that I would consider:
Firstly, the family - they need to be talked to! Firstly who is the doctor? The family members are helpful as purveyors of information for Dad but they aren't doctors, they are CHILDREN of the patient. You might consider handing the patient over to some-one else and acting as an overseer to verify that all is done properly.
Secondly, the issue is - do they want Dad cured or not? The side effects are affected by your volumes, but also by his radiosensitivity and his underlying condition. No RT or surgical cure came by backing off treatment. The least morbid treatment is the "one-stop shop". Laser resection will be OK once but with recurrence will enhance aspiration with second attempt or salvage RT, and won't address the neck LNs. RT reigns supreme for him.
Thirdly, my personal impression is that his cure potential is the same as a younger patient, his toxicity potential is equal, but his ability to cope with and rebound from the toxicity is much poorer.
Fourthly, I would consider an concurrent adjunct therapy like cetuximab, but not chemo.
Fifthly, the side effects will be related to the fineness of the voluming and the CTV>PTV margin which will relate to your IGRT protocol.
Sixthly, if I was to be trotting out the piece de resistance treatment, I would ask for an IGRT approach with a dead-on set up margin. I would get a PET to help delineate extent in mucosa (a rough guide), and then contour the mucosa and build a mucosa_PRV structure to limit dose in the posterior pharyngeal wall. (I do this by autocontouring the air-tissue interface, expanding to a 2mm larger structure and then subtracting the first from the second to leave an annulus which I call "MUCOSA". I expand my PTV6000 by 7mm to form a theoretical construct called the PTV_PRV and then take the MUCOSA, expand by the setup margin (1-2mm) and exclude from inside the PTV_PRV, and I am then left with the MUCOSA_PRV which is more than 7mm from the PTV6000. This is the mucosa that can be conserved and so should get a high priority in the IMRT constraints.) This method would result in minimised mucosal doses.
The neck volumes are largely irrelevant w.r.t the toxicity.